New insights into platelet function testing: From bench to bedside

• References

• 1 Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929.
• 2 Born GV. Inhibition of thrombogenesis by inhibition of platelet aggregation. Thromb Diath Haemorrh Suppl 1966; 21: 159-166.
• 3 Sibbing D, Byrne RA, Bernlochner I. et al. High platelet reactivity and clinical outcome - Fact or Fiction. Thromb Haemost 2011; 106: 191-202.
• 4 Fefer P, Matetzky S. The genetic basis of platelet responsiveness to clopidogrel: A critical review of the literature. Thromb Haemost 2011; 106: 203-210.
• 5 Gremmel T, Panzer S. Clinical, genetic and confounding factors determine the dynamics of the in vitro response/non response to clopidogrel. Thromb Haemost 2011; 106: 211-218.
• 6 Frelinger AL, Michelson AD, Wiviott SD. et al. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high level P2Y12 blockade by prasugrel or highdose clopidogrel: Results from PRINCIPLE-TIMI 44. Thromb Haemost 2011; 106: 219-226.
• 7 Voisin S, Bongard V, Tidjane MA. et al. Are P2Y12 reaction unit (PRU) and % inhibition index equivalent for the expression of P2Y12 inhibition by the VerifyNow® assay? Role of haematocrit and haemoglobin levels. Thromb Haemost 2011; 106: 227-229.
• 8 Freynhofer MK, Brozovic I, Bruno V. et al. Multiple electrode aggregometry and vasodilator-stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events. Thromb Haemost 2011; 106: 230-239.
• 9 Halawani SHM, Williams DJP, Webster J. et al. Aspirin failure in patients presenting with acute cerebrovascular ischaemia. Thromb Haemost 2011; 106: 240-247.
• 10 Gurbel PA, Mahla E, Tantry US. Peri-operative platelet function testing: The potential for reducing ischaemic and bleeding risks. Thromb Haemost 2011; 106: 248-252.
• 11 Angiolillo DJ, Capranzano P, Ferreiro JL. et al. Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. Thromb Haemost 2011; 106: 253-262.
• 12 Gurbel PA, Tantry US, Bliden KP. et al. Immunity to thrombotic events is achievable if we stop the guessing game: Is this the major hidden message from GRAVITAS?. Thromb Haemost 2011; 106: 263-264.
• 13 Salles I, Broos K, Fontayne A. et al. Development of a high-throughput ELISA assay for platelet function testing using platelet-rich plasma or whole blood. Thromb Haemost 2010; 104: 392-401.
• 14 Judge HM, Buckland RJ, Sugidachi A. et al. Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function. Thromb Haemost. 2010; 103: 1210-1217.
• 15 Bertling A, Niemann S, Uekötter A. et al. Candida albicans and its metabolite gliotoxin inhibit platelet function via interaction with thiols. Thromb Haemost 2010; 104: 270-278.
• 16 Grove EL, Hvas AM, Johnsen HL. et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010; 103: 1245-1253.
• 17 van der Wal DE, Verhoef S, Schutgens RE. et al. Role of glycoprotein Ibalpha mobility in platelet function. Thromb Haemost 2010; 103: 1033-1043.
• 18 Bouman HJ, van Werkum JW, Rudez G. et al. The influence of variation in the P2Y12 receptor gene on in vitro platelet inhibition with the direct P2Y12 antagonist cangrelor. Thromb Haemost 2010; 103: 379-386.
• 19 Brambilla M, Parolari A, Camera M. et al. Effect of two doses of aspirin on thromboxane biosynthesis and platelet function in patients undergoing coronary surgery. Thromb Haemost 2010; 103: 516-524.
• 20 Ferreiro JL, Sibbing D, Angiolillo DJ. Platelet function testing and risk of bleeding complications. Thromb Haemost 2010; 103: 1128-1135.